BCG X’s Post

Exciting developments in the realm of #AI and #ML in drug development from Luka Jelcic! Luka revisited an insightful post from nearly 9 months ago, discussing key players who are AI-first with their own assets in development. As the debate continues on what truly constitutes an AI/ML-developed drug, he plans to update this overview in the coming days. We're keen to hear your thoughts on who else should be included. How do you classify an asset where AI/ML has played a significant role? Stay tuned for Luka's upcoming report on how biopharma leverages AI, featuring insights from interviews with 10 senior leaders and experts from major biopharma organizations. #DrugDevelopment #Biopharma

AI promises to make drug discovery and development faster and cheaper, and may even identify completely new drugs beyond the reach of traditional methods. By analysing 10 years of #biopharma deals, we set out to capture the impact of AI on biopharma deal-making. In this paper, we identify the key trends and insights that can support M&A and business development teams as they shape their strategies to empower their organisations with AI capabilities. https://pwcch.smh.re/ffj #ai #pwc

#AI holds the potential to accelerate and reduce costs in drug discovery, possibly uncovering entirely new drugs not attainable through traditional methods. With the early successes and the advances in AI technologies, its disruptive nature when it comes to drug discovery is undeniable. Through a comprehensive analysis of 10 years of #biopharma deals, we aim to unveil the impact of AI on biopharma deal-making. Our paper identifies crucial trends and insights to assist M&A and business development teams in shaping strategies that empower their organisations with AI capabilities.

When i choose a company to work for, all what i am keen about is its consistent innovative culture that will leverage my challenger mindset and that is what i found at Sanofi since day one. AI is the future. So, What does it mean to be all in on AI? 🔬 At Sanofi, we’re giving all of our employees access to better decision intelligence through “snackable AI” and doubling down on “expert” AI to help our R&D teams find the next breakthrough medicines and vaccines. To learn more about our ambition to become the first pharma company using AI at scale, see this clip with our own CEO, Paul Hudson, or watch the full interview here: http://spkl.io/60414qWBR #Technology #AI #ScienceAndTechnology #PursureProgress #WeNeverSettle #discoverextraordinary

I am happy to announce that I have finalized the #AI report that I was working on the past couple of months! In the report you will find the feedback from interviewing 10 senior #biopharma experts on their usage of AI in #drug #discovery and #development (AIDD). Follow the link below if interested to find out more!

#AI promises to make drug discovery and development faster and cheaper, and may even identify completely new drugs beyond the reach of traditional methods. By analysing 10 years of #biopharma deals, we set out to capture the impact of AI on biopharma deal-making. In this paper, we identify the key trends and insights that can support M&A and business development teams as they shape their strategies to empower their organisations with AI capabilities.

#AI holds the potential to accelerate and reduce costs in drug discovery, possibly uncovering entirely new drugs not attainable through traditional methods. With the early successes and the advances in AI technologies, its disruptive nature when it comes to drug discovery is undeniable. Through a comprehensive analysis of 10 years of #biopharma deals, we aim to unveil the impact of AI on biopharma deal-making. Our paper identifies crucial trends and insights to assist M&A and business development teams in shaping strategies that empower their organisations with AI capabilities.

#AI holds the potential to accelerate and reduce costs in drug discovery, possibly uncovering entirely new drugs not attainable through traditional methods. With the early successes and the advances in AI technologies, its disruptive nature when it comes to drug discovery is undeniable. Through a comprehensive analysis of 10 years of #biopharma deals, we aim to unveil the impact of AI on biopharma deal-making. Our paper identifies crucial trends and insights to assist M&A and business development teams in shaping strategies that empower their organisations with AI capabilities.

#AI promises to make drug discovery and development faster and cheaper, and may even identify completely new drugs beyond the reach of traditional methods. By analysing 10 years of #biopharma deals, we set out to capture the impact of AI on biopharma deal-making. In this paper, we identify the key trends and insights that can support M&A and business development teams as they shape their strategies to empower their organisations with AI capabilities.

How is AI used most frequently in pharma R&D? What ROI have biopharma leaders seen from using AI so far? These are some of the questions Luka Jelcic asked 10 senior biopharma leaders in our latest AI in Drug Discovery and Development (AIDD) Ad Board! This Ad Board covers key themes on the key use cases of AI, unmet needs, ROI seen by leveraging AI approaches, as well as in-depth perceptions of key AI vendors in the space. Interested in learning more? Follow the link to the full report or reach out directly to Luka! AI in Drug Discovery and Development Report: https://lnkd.in/gHej8Ajq #biopharma #AI #drugdiscovery #ROI